Evaluation of rapid antigen tests using nasal samples to diagnose SARS-CoV-2 in symptomatic patients
Introduction: The best way to mitigate an outbreak besides mass vaccination is via early detection and isolation of infected cases. As such, a rapid, cost-effective test for the early detection of COVID-19 is required.
Methods: The study included 4,183 mildly symptomatic patients. A nasal and nasopharyngeal sample obtained from each patient was analyzed to determine the diagnostic ability of the rapid antigen detection test (RADT, nasal swab) in comparison with the current gold-standard (RT-PCR, nasopharyngeal swab).
Results: The calculated sensitivity and specificity of the RADT was 82.1 and 99.1%, respectively. Kappa's coefficient of agreement between the RADT and RT-PCR was 0.859 (p < 0.001). Stratified analysis showed that the sensitivity of the RADT improved significantly when lowering the cut-off RT-PCR Ct value to 24.
Conclusion: Our study's results support the potential use of nasal swab RADT as a screening tool in mildly symptomatic patients, especially in patients with higher viral loads.
CommentsThe original article is available at https://www.frontiersin.org/
Published CitationAlqahtani M. et al. Evaluation of rapid antigen tests using nasal samples to diagnose SARS-CoV-2 in symptomatic patients. Front Public Health. 2022;9:728969
Publication Date14 January 2022
- RCSI Bahrain
PublisherFrontiers Editorial Office
- Published Version (Version of Record)